Two phase 3 RCTs found olezarsen reduced triglycerides versus placebo in patients with severe hypertriglyceridemia and diabetes, with fewer acute pancreatitis events during treatment.
The observational B-MORE study reported a median annualized bleeding rate of 0.5 with rFIXFc prophylaxis, alongside fewer injections and lower factor consumption than prior standard half-life therapy.
The randomized controlled trial found mobile PrEP and MOUD services did not improve medication use versus peer navigation alone among people who inject drugs, although mortality was lower.
A retrospective cohort study of 587 patients with metastatic cancer linked influenza vaccination during checkpoint inhibitor therapy to longer progression-free survival, without significantly higher IRAE...
A post hoc phase 3 analysis found vutrisiran attenuated left atrial strain deterioration versus placebo at 30 months in ATTR-CM, while worse baseline function predicted adverse outcomes.
An English cohort emulating a randomized trial linked influenza vaccination to lower influenza hospitalization risk in adults ≥40 with COPD, although residual confounding remained.